Immuno Oncology Assays Market Global Report 2026

The immuno oncology assays market size has grown rapidly in recent years. It will grow from $4.88 billion in 2025 to $5.52 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth during the historic period can be attributed to the increasing prevalence of cancer cases worldwide, rising investment in cancer immunotherapy research, growing adoption of biomarker-based cancer diagnostics, increasing demand for personalized medicine approaches, and expanding clinical research activities in oncology.

The immuno oncology assays market size is expected to see rapid growth in the next few years. It will grow to $8.9 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth during the forecast period can be attributed to rising demand for advanced immune profiling assays, increasing adoption of precision oncology strategies, growing development of novel cancer immunotherapies, expanding use of predictive biomarkers for treatment selection, and increasing collaborations between pharmaceutical companies and research institutions. Major trends in the forecast period include increasing adoption of multiplex immuno-oncology assays for comprehensive biomarker analysis, rising demand for companion diagnostics in cancer immunotherapy development, growing focus on immune profiling for personalized oncology treatment strategies, increasing utilization of biomarker-based clinical trial approaches, and rising demand for advanced assay platforms supporting rapid cancer research workflows.

The increasing prevalence of cancer cases is expected to drive the growth of the immuno-oncology assays market going forward. Cancer cases refer to the number of individuals diagnosed with any type of cancer within a specific population, region, or period and serve as a key indicator of disease burden and healthcare requirements. The prevalence of cancer is increasing due to factors such as rising tobacco and alcohol consumption, as these behaviors expose individuals to carcinogenic substances that damage cells, increase genetic mutations, and substantially raise the risk of developing various cancers, including lung, liver, oral, and esophageal cancers. Immuno-oncology assays support cancer diagnosis and treatment by identifying tumor-specific biomarkers, assessing immune responses, guiding personalized immunotherapy selection, and monitoring treatment outcomes. For instance, in January 2026, according to the Centers for Disease Control and Prevention, a US-based public health agency, the United States recorded approximately 1.85 million new cancer cases in 2022, while cancer accounted for 613,349 deaths in 2023. Therefore, the increasing prevalence of cancer cases is driving the growth of the immuno-oncology assays market.

Major companies operating in the immuno-oncology assays market are focusing on developing innovative solutions such as liquid biopsy immunotherapy response monitoring assays to improve early treatment response assessment, optimize therapeutic decision-making, and enhance precision oncology outcomes. Liquid biopsy immunotherapy response monitoring assays are molecular diagnostic tests that analyze circulating tumor DNA (ctDNA) from blood samples to assess patient responses to immune checkpoint inhibitor therapies over time. These assays provide a less invasive and earlier alternative to conventional imaging-based assessments while allowing clinicians to identify molecular changes before clinical disease progression becomes evident. For instance, in June 2025, Tempus AI Inc., a US-based precision medicine company, launched xM for Treatment Response Monitoring (TRM), a liquid biopsy assay designed to monitor molecular responses to immune checkpoint inhibitor therapy in patients with advanced solid tumors. The assay measures changes in circulating tumor DNA using a multi-parametric algorithm that combines copy number variations with somatic and germline variant allele frequencies to estimate circulating tumor fraction with high sensitivity. It enables clinicians and researchers to identify molecular responses before six weeks of treatment, supporting earlier therapeutic interventions and more refined treatment strategies. Initially introduced for research use, the assay expands Tempus' molecular monitoring portfolio in immuno-oncology and is expected to become clinically available following its research deployment.

In July 2025, Quanterix Corporation, a US-based healthcare technology company, acquired Akoya Biosciences Inc. for an undisclosed amount. Through this acquisition, Quanterix aims to establish the first integrated platform capable of measuring biomarkers across the blood and tissue continuum, strengthening its position in precision medicine and expanding its capabilities in oncology, neurology, and immunology research. Akoya Biosciences Inc. is a US-based healthcare technology company specializing in immuno-oncology (IO) assays and validated IO-focused panels for spatial biology and tissue-based biomarker analysis.

Major companies operating in the immuno oncology assays market are Thermo Fisher Scientific Inc, F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company, Merck KGaA, Labcorp Holdings Inc, Agilent Technologies Inc, Sysmex Corporation, Illumina Inc, Revvity Inc, Charles River Laboratories International Inc, Bio-Rad Laboratories Inc, QIAGEN N.V., Bruker Corporation, Natera Inc, Tempus AI Inc, Promega Corporation, Guardant Health Inc, NeoGenomics Inc, Bio-Techne Corporation, Myriad Genetics Inc, Adaptive Biotechnologies Corporation.

North America was the dominant region in the immuno oncology assays market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the immuno oncology assays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the immuno oncology assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.